<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172639</url>
  </required_header>
  <id_info>
    <org_study_id>CareRA</org_study_id>
    <secondary_id>2008-007225-39</secondary_id>
    <nct_id>NCT01172639</nct_id>
  </id_info>
  <brief_title>Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.</brief_title>
  <official_title>A 2 Year Prospective Multicentre Randomised Controlled Trial Comparing Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>P. Verschueren</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Combinatietherapie Bij Reumatoide Artritis (CoBRA) trial was a milestone in the
      development of the present treatment paradigm for Rheumatoid Arthritis (RA). This study
      introduced the principle of fast remission induction by means of a combination of standard
      Disease Modifying AntiRheumatic Drugs (DMARDs) and a step down bridge therapy with high dose
      glucocorticoids in early Rheumatoid Arthritis.

      The purpose of the present study is to compare different combinations of traditional DMARDs
      and glucocorticoids, based on the original CoBRA protocol, for treatment of early Rheumatoid
      Arthritis.

      Besides the efficacy and effectiveness of these strategies, patient centered outcomes and
      potential implementation problems of such treatment strategies are evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Before randomisation patients were stratified to a high-risk or low-risk group according to the presence of risk factors at screening (having erosions, rheumatoid factor and/or anticitrullinated protein antibody and a high disease activity score calculated with C-reactive protein (DAS28-CRP)). Randomisation to treatment arms was performed via a digitally generated sequence. Patients in the high-risk group were randomised into CoBRA Classic, Clim or Avant-Garde arm. Patients in the low-risk group were randomised into CoBRA Slim or Tight Step Up arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission According to DAS28-CRP at Week 16</measure>
    <time_frame>week 16</time_frame>
    <description>Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 16.
DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).
A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission According to DAS28-CRP at Week 52</measure>
    <time_frame>week 52</time_frame>
    <description>Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 52. (co-primary end point)
DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).
A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission According to DAS28-CRP at Week 104</measure>
    <time_frame>week 104</time_frame>
    <description>Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 104. (co-primary endpoints)
DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).
A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission According to SDAI (Simple Disease Activity Index) at Week 16</measure>
    <time_frame>week 16</time_frame>
    <description>Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 16.
SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.
A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission According to SDAI at Week 52</measure>
    <time_frame>week 52</time_frame>
    <description>Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 52.
SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.
A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission According to SDAI at Week 104</measure>
    <time_frame>week 104</time_frame>
    <description>Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 104.
SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.
A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Change in HAQ Score</measure>
    <time_frame>Baseline-week104</time_frame>
    <description>Number of patients with a change of &gt; 0.22 in the Health Assessment Questionnaire (HAQ) score over the period between baseline and week 104.
A change of &gt; 0.22 in this score is considered as clinical relevant for rheumatoid arthritis patients.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CoBRA classic high risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Methotrexate 15mg tablet by mouth, weekly for entire trial
Sulfasalazine 2g tablet by mouth, daily for 40 weeks
Prednisone tablet by mouth, weekly step down scheme 60 - 40 - 25 - 20 - 15 - 10 mg daily for 6 weeks, followed by 7.5mg daily till week 28, then further tapered down to stop at week 32</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CoBRA slim high risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Methotrexate 15mg tablet by mouth, weekly for entire trial
Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CoBRA avant-garde high risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Methotrexate 15mg tablet by mouth, weekly for 40 weeks (continued for entire trial if randomized to Methotrexate monotherapy at week 40)
Leflunomide 10mg tablet by mouth, daily for 40 weeks (continued for entire trial if randomized to Leflunomide monotherapy at week 40)
Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CoBRA slim low risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Methotrexate 15mg tablet by mouth, weekly for entire trial
Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tight Step Up low risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Methotrexate 15mg tablet by mouth, weekly for entire trial
No oral steroids allowed during the first year of the trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate tablet</description>
    <arm_group_label>CoBRA avant-garde high risk group</arm_group_label>
    <arm_group_label>CoBRA classic high risk group</arm_group_label>
    <arm_group_label>CoBRA slim high risk group</arm_group_label>
    <arm_group_label>CoBRA slim low risk group</arm_group_label>
    <arm_group_label>Tight Step Up low risk group</arm_group_label>
    <other_name>Ledertrexate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfasalazine</intervention_name>
    <description>Sulfasalazine tablet</description>
    <arm_group_label>CoBRA classic high risk group</arm_group_label>
    <other_name>Salazopyrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leflunomide</intervention_name>
    <description>Leflunomide tablet</description>
    <arm_group_label>CoBRA avant-garde high risk group</arm_group_label>
    <other_name>Arava</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone tablet</description>
    <arm_group_label>CoBRA avant-garde high risk group</arm_group_label>
    <arm_group_label>CoBRA classic high risk group</arm_group_label>
    <arm_group_label>CoBRA slim high risk group</arm_group_label>
    <arm_group_label>CoBRA slim low risk group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA as defined by the 1987 or 2010 revised American College of
             Rheumatology (ACR) criteria

          -  Early RA (less than 1 year)

          -  Use a reliable method of contraception for women of childbearing potential

          -  Able and willing to give written informed consent and participate in the study

        Exclusion Criteria:

          -  Previous treatment with DMARDs

          -  Previous treatment with oral corticosteroids at a dosage of more than 10 milligrams
             (mg) prednisone within 4 weeks before baseline

          -  Previous treatment with oral corticosteroids at a dosage equal to or less than 10 mg
             prednisone within 2 weeks before baseline

          -  Previous treatment with oral corticosteroids for more than 4 weeks

          -  Previous treatment with Intra Articular corticosteroids within 4 weeks before baseline

          -  Previous treatment with an investigational drug for the treatment or prevention of RA

          -  Contraindications for corticosteroids

          -  Contraindications for DMARDs

          -  Psoriatic Arthritis

          -  Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions,
             chronic or latent infectious diseases or immune deficiency which in the opinion of the
             investigator places the patient at an unacceptable risk for participation in the study

          -  Pregnancy, breastfeeding or no use of a reliable method of contraception

          -  Alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Verschueren, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASZ</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St Lucas</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reuma praktijk</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumacentrum</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent, dept. of Rheumatology</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reuma instituut Hasselt</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumapraktijk</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jan Yperman Ziekenhuis</name>
      <address>
        <city>Ieper</city>
        <zip>8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HHart Ziekenhuis</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCH</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St maarten</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Jan Palfijn</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henri Serruys ziekenhuis</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Verschueren P, Esselens G, Westhovens R. Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol. 2009 May-Jun;38(3):166-72. doi: 10.1080/03009740802484846.</citation>
    <PMID>19169906</PMID>
  </reference>
  <reference>
    <citation>Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford). 2008 Jan;47(1):59-64. Epub 2007 Nov 26.</citation>
    <PMID>18039681</PMID>
  </reference>
  <reference>
    <citation>Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007 Dec;56(12):3919-27.</citation>
    <PMID>18050189</PMID>
  </reference>
  <reference>
    <citation>Esselens G, Westhovens R, Verschueren P. Effectiveness of an integrated outpatient care programme compared with present-day standard care in early rheumatoid arthritis. Musculoskeletal Care. 2009 Mar;7(1):1-16. doi: 10.1002/msc.136.</citation>
    <PMID>18618520</PMID>
  </reference>
  <reference>
    <citation>Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997 Aug 2;350(9074):309-18. Erratum in: Lancet 1998 Jan 17;351(9097):220.</citation>
    <PMID>9251634</PMID>
  </reference>
  <reference>
    <citation>De Cock D, Van der Elst K, Meyfroidt S, Verschueren P, Westhovens R. The optimal combination therapy for the treatment of early rheumatoid arthritis. Expert Opin Pharmacother. 2015;16(11):1615-25. doi: 10.1517/14656566.2015.1056735. Epub 2015 Jun 10. Review.</citation>
    <PMID>26058860</PMID>
  </reference>
  <results_reference>
    <citation>Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015 Jan;74(1):27-34. doi: 10.1136/annrheumdis-2014-205489. Epub 2014 Oct 30.</citation>
    <PMID>25359382</PMID>
  </results_reference>
  <results_reference>
    <citation>Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Van der Elst K, Meyfroidt S, Westhovens R; CareRA study group. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther. 2015 Apr 9;17:97. doi: 10.1186/s13075-015-0611-8.</citation>
    <PMID>25889222</PMID>
  </results_reference>
  <results_reference>
    <citation>Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis. 2017 Mar;76(3):511-520. doi: 10.1136/annrheumdis-2016-209212. Epub 2016 Jul 18.</citation>
    <PMID>27432356</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2010</study_first_posted>
  <results_first_submitted>May 16, 2018</results_first_submitted>
  <results_first_submitted_qc>May 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2018</results_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>P. Verschueren</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>CoBRA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We recruited 400 participants between January 2009 and May 2013. There were 13 participating Flemish rheumatology centers (2 academic centers, 7 general hospitals and 4 private practices).</recruitment_details>
      <pre_assignment_details>There were 379 patients randomised to a treatment arm, 21 patients not randomised: 1 screen failure, 10 withdrawals by subject, 10 randomisation errors</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CoBRA Classic High Risk Group</title>
          <description>Methotrexate 15mg tablet by mouth, weekly for entire trial
Sulfasalazine 2g tablet by mouth, daily for 40 weeks
Prednisone tablet by mouth, weekly step down scheme 60 - 40 - 25 - 20 - 15 - 10 mg daily for 6 weeks, followed by 7.5mg daily till week 28, then further tapered down to stop at week 32</description>
        </group>
        <group group_id="P2">
          <title>CoBRA Slim High Risk Group</title>
          <description>Methotrexate 15mg tablet by mouth, weekly for entire trial
Prednisone tablet by mouth, weekly step down scheme 30 – 20 – 12.5 – 10 – 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32</description>
        </group>
        <group group_id="P3">
          <title>CoBRA Avant-garde High Risk Group</title>
          <description>Methotrexate 15mg tablet by mouth, weekly for 40 weeks (continued for entire trial if randomized to Methotrexate monotherapy at week 40)
Leflunomide 10mg tablet by mouth, daily for 40 weeks (continued for entire trial if randomized to Leflunomide monotherapy at week 40)
Prednisone tablet by mouth, weekly step down scheme 30 – 20 – 12.5 – 10 – 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32</description>
        </group>
        <group group_id="P4">
          <title>CoBRA Slim Low Risk Group</title>
          <description>Methotrexate 15mg tablet by mouth, weekly for entire trial
Prednisone tablet by mouth, weekly step down scheme 30 – 20 – 12.5 – 10 – 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32</description>
        </group>
        <group group_id="P5">
          <title>Tight Step Up Low Risk Group</title>
          <description>Methotrexate 15mg tablet by mouth, weekly for entire trial
No oral steroids allowed during the first year of the trial</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 16</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 52</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CoBRA Classic High Risk Group</title>
          <description>Methotrexate (MTX)
Sulphasalazine
Step down steroid full dose
randomisation: Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.</description>
        </group>
        <group group_id="B2">
          <title>CoBRA Slim High Risk Group</title>
          <description>MTX
Step down steroid half dose
randomisation: Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.</description>
        </group>
        <group group_id="B3">
          <title>CoBRA Avant-garde High Risk Group</title>
          <description>MTX
Leflunomide
Step down steroid half dose
randomisation: Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.</description>
        </group>
        <group group_id="B4">
          <title>CoBRA Slim Low Risk Group</title>
          <description>MTX
Step down steroid half dose
randomisation: Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.</description>
        </group>
        <group group_id="B5">
          <title>Tight Step Up Low Risk Group</title>
          <description>MTX
No additional oral steroids allowed
randomisation: Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="93"/>
            <count group_id="B4" value="43"/>
            <count group_id="B5" value="47"/>
            <count group_id="B6" value="379"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="11.9"/>
                    <measurement group_id="B2" value="51.8" spread="13.1"/>
                    <measurement group_id="B3" value="51.1" spread="12.8"/>
                    <measurement group_id="B4" value="51.4" spread="14.4"/>
                    <measurement group_id="B5" value="51.0" spread="14.0"/>
                    <measurement group_id="B6" value="51.9" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="262"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>past</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptom duration</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="35.5"/>
                    <measurement group_id="B2" value="33.2" spread="38.2"/>
                    <measurement group_id="B3" value="44.3" spread="65.9"/>
                    <measurement group_id="B4" value="34.4" spread="68.2"/>
                    <measurement group_id="B5" value="33.1" spread="62.2"/>
                    <measurement group_id="B6" value="36.2" spread="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission According to DAS28-CRP at Week 16</title>
        <description>Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 16.
DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).
A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity.</description>
        <time_frame>week 16</time_frame>
        <population>ITT = intention to treat analysis (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
        <group_list>
          <group group_id="O1">
            <title>CoBRA Classic High Risk Group</title>
            <description>Methotrexate (MTX)
Sulphasalazine
Step down steroid full dose</description>
          </group>
          <group group_id="O2">
            <title>CoBRA Slim High Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O3">
            <title>CoBRA Avant-garde High Risk Group</title>
            <description>MTX
Leflunomide
Step down steroid half dose</description>
          </group>
          <group group_id="O4">
            <title>CoBRA Slim Low Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O5">
            <title>Tight Step Up Low Risk Group</title>
            <description>MTX
No additional oral steroids allowed</description>
          </group>
        </group_list>
        <measure>
          <title>Remission According to DAS28-CRP at Week 16</title>
          <description>Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 16.
DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).
A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity.</description>
          <population>ITT = intention to treat analysis (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Remission According to DAS28-CRP at Week 52</title>
        <description>Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 52. (co-primary end point)
DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).
A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity.</description>
        <time_frame>week 52</time_frame>
        <population>ITT (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
        <group_list>
          <group group_id="O1">
            <title>CoBRA Classic High Risk Group</title>
            <description>Methotrexate (MTX)
Sulphasalazine
Step down steroid full dose</description>
          </group>
          <group group_id="O2">
            <title>CoBRA Slim High Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O3">
            <title>CoBRA Avant-garde High Risk Group</title>
            <description>MTX
Leflunomide
Step down steroid half dose</description>
          </group>
          <group group_id="O4">
            <title>CoBRA Slim Low Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O5">
            <title>Tight Step Up Low Risk Group</title>
            <description>MTX
No additional oral steroids allowed</description>
          </group>
        </group_list>
        <measure>
          <title>Remission According to DAS28-CRP at Week 52</title>
          <description>Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 52. (co-primary end point)
DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).
A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity.</description>
          <population>ITT (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Remission According to DAS28-CRP at Week 104</title>
        <description>Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 104. (co-primary endpoints)
DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).
A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity.</description>
        <time_frame>week 104</time_frame>
        <population>ITT (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
        <group_list>
          <group group_id="O1">
            <title>CoBRA Classic High Risk Group</title>
            <description>Methotrexate (MTX)
Sulphasalazine
Step down steroid full dose</description>
          </group>
          <group group_id="O2">
            <title>CoBRA Slim High Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O3">
            <title>CoBRA Avant-garde High Risk Group</title>
            <description>MTX
Leflunomide
Step down steroid half dose</description>
          </group>
          <group group_id="O4">
            <title>CoBRA Slim Low Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O5">
            <title>Tight Step Up Low Risk Group</title>
            <description>MTX
No additional oral steroids allowed</description>
          </group>
        </group_list>
        <measure>
          <title>Remission According to DAS28-CRP at Week 104</title>
          <description>Number of patients in remission according to DAS28-CRP (Disease Activity Score based on 28 joint count and C-reactive Protein) at week 104. (co-primary endpoints)
DAS28-CRP is calculated with the following formula : 0.56*SQRT TJC28+0.28*SQRT SJC28+0.36*ln (CRP+1)+0.014*GH+0.96 in which TJC is the tender joint count, SJC the Swollen Joint Count and GH the general health estimated by the patient on a Visual Analogue Scale (VAS).
A value below 2.6 is indicating remission, below or equal to 3.2 low disease activity, between 3.2 and 5.1 moderate disease activity and above 5.1 high disease activity.</description>
          <population>ITT (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission According to SDAI (Simple Disease Activity Index) at Week 16</title>
        <description>Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 16.
SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.
A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity.</description>
        <time_frame>week 16</time_frame>
        <population>ITT (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
        <group_list>
          <group group_id="O1">
            <title>CoBRA Classic High Risk Group</title>
            <description>Methotrexate (MTX)
Sulphasalazine
Step down steroid full dose</description>
          </group>
          <group group_id="O2">
            <title>CoBRA Slim High Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O3">
            <title>CoBRA Avant-garde High Risk Group</title>
            <description>MTX
Leflunomide
Step down steroid half dose</description>
          </group>
          <group group_id="O4">
            <title>CoBRA Slim Low Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O5">
            <title>Tight Step Up Low Risk Group</title>
            <description>MTX
No additional oral steroids allowed</description>
          </group>
        </group_list>
        <measure>
          <title>Remission According to SDAI (Simple Disease Activity Index) at Week 16</title>
          <description>Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 16.
SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.
A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity.</description>
          <population>ITT (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission According to SDAI at Week 52</title>
        <description>Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 52.
SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.
A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity.</description>
        <time_frame>week 52</time_frame>
        <population>ITT (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
        <group_list>
          <group group_id="O1">
            <title>CoBRA Classic High Risk Group</title>
            <description>Methotrexate (MTX)
Sulphasalazine
Step down steroid full dose</description>
          </group>
          <group group_id="O2">
            <title>CoBRA Slim High Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O3">
            <title>CoBRA Avant-garde High Risk Group</title>
            <description>MTX
Leflunomide
Step down steroid half dose</description>
          </group>
          <group group_id="O4">
            <title>CoBRA Slim Low Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O5">
            <title>Tight Step Up Low Risk Group</title>
            <description>MTX
No additional oral steroids allowed</description>
          </group>
        </group_list>
        <measure>
          <title>Remission According to SDAI at Week 52</title>
          <description>Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 52.
SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.
A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity.</description>
          <population>ITT (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission According to SDAI at Week 104</title>
        <description>Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 104.
SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.
A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity.</description>
        <time_frame>week 104</time_frame>
        <population>ITT = intention to treat analysis (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
        <group_list>
          <group group_id="O1">
            <title>CoBRA Classic High Risk Group</title>
            <description>Methotrexate (MTX)
Sulphasalazine
Step down steroid full dose</description>
          </group>
          <group group_id="O2">
            <title>CoBRA Slim High Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O3">
            <title>CoBRA Avant-garde High Risk Group</title>
            <description>MTX
Leflunomide
Step down steroid half dose</description>
          </group>
          <group group_id="O4">
            <title>CoBRA Slim Low Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O5">
            <title>Tight Step Up Low Risk Group</title>
            <description>MTX
No additional oral steroids allowed</description>
          </group>
        </group_list>
        <measure>
          <title>Remission According to SDAI at Week 104</title>
          <description>Number of patients in remission according to SDAI (Simplified Disease Activity Index) at week 104.
SDAI is calculated with the following formula : TJC28+SJC28+GH+GA ph in which TJC is the number of tender joints, SJC the number of Swollen Joint and GH the general health assessed by the patient on a Visual Analogue Scale (VAS) and GA ph the general assessment of the physician on a VAS.
A value below 3.3 is indicating remission, between 3.4 and 11.0 low disease activity, between 11.1 and 26.0 moderate disease activity and above 26.0 high disease activity.</description>
          <population>ITT = intention to treat analysis (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Change in HAQ Score</title>
        <description>Number of patients with a change of &gt; 0.22 in the Health Assessment Questionnaire (HAQ) score over the period between baseline and week 104.
A change of &gt; 0.22 in this score is considered as clinical relevant for rheumatoid arthritis patients.</description>
        <time_frame>Baseline-week104</time_frame>
        <population>ITT = intention to treat analysis (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
        <group_list>
          <group group_id="O1">
            <title>CoBRA Classic High Risk Group</title>
            <description>Methotrexate (MTX)
Sulphasalazine
Step down steroid full dose</description>
          </group>
          <group group_id="O2">
            <title>CoBRA Slim High Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O3">
            <title>CoBRA Avant-garde High Risk Group</title>
            <description>MTX
Leflunomide
Step down steroid half dose</description>
          </group>
          <group group_id="O4">
            <title>CoBRA Slim Low Risk Group</title>
            <description>MTX
Step down steroid half dose</description>
          </group>
          <group group_id="O5">
            <title>Tight Step Up Low Risk Group</title>
            <description>MTX
No additional oral steroids allowed</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Change in HAQ Score</title>
          <description>Number of patients with a change of &gt; 0.22 in the Health Assessment Questionnaire (HAQ) score over the period between baseline and week 104.
A change of &gt; 0.22 in this score is considered as clinical relevant for rheumatoid arthritis patients.</description>
          <population>ITT = intention to treat analysis (all randomized subjects included), missing data imputed with Expectation Maximization on complete w104 database.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over a two year period per patient</time_frame>
      <desc>All adverse events were registered by healthcare professionals questioning the patients at each visit</desc>
      <group_list>
        <group group_id="E1">
          <title>CoBRA Classic High Risk Group</title>
          <description>Methotrexate (MTX)
Sulphasalazine
Step down steroid full dose
randomisation: Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.</description>
        </group>
        <group group_id="E2">
          <title>CoBRA Slim High Risk Group</title>
          <description>MTX
Step down steroid half dose
randomisation: Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.</description>
        </group>
        <group group_id="E3">
          <title>CoBRA Avant-garde High Risk Group</title>
          <description>MTX
Leflunomide
Step down steroid half dose
randomisation: Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.</description>
        </group>
        <group group_id="E4">
          <title>CoBRA Slim Low Risk Group</title>
          <description>MTX
Step down steroid half dose
randomisation: Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.</description>
        </group>
        <group group_id="E5">
          <title>Tight Step Up Low Risk Group</title>
          <description>MTX
No additional oral steroids allowed
randomisation: Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bone marrow supression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Atrioventricular block third degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sinus venosus defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Uncontrolled diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis after a wasp sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Septic bursitis olecrani</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia diaphragmatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Ischialgy leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lumbago</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis flare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Baker's cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer malignant</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cervixcarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Endometrioid adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Intestinal polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Kidney cancer malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lung cancer malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lung noduli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neoplasms parotid gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Noduli submandibular salivary glands</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diffuse pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <description>induced by MTX</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Severe depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Peribronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Orthopaedic surgery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Abdominal surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Amygdalectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Liposuction arms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pulmonary embolisms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Peripheral vascular ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="98"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="98"/>
                <counts group_id="E3" events="46" subjects_affected="37" subjects_at_risk="93"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="98"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="93"/>
                <counts group_id="E4" events="14" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E3" events="28" subjects_affected="24" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pyrosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General malaise</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hairloss</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="98"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="93"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Increased transpiration</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Flushes</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sjogren's disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver function disturbance</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="98"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E3" events="25" subjects_affected="24" subjects_at_risk="93"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="93"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Aphtosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="93"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="98"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="98"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="93"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E5" events="13" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rotator cuff lesion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Tendinopathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="93"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Arthrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="98"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="50" subjects_affected="28" subjects_at_risk="98"/>
                <counts group_id="E2" events="72" subjects_affected="42" subjects_at_risk="98"/>
                <counts group_id="E3" events="46" subjects_affected="29" subjects_at_risk="93"/>
                <counts group_id="E4" events="29" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E5" events="40" subjects_affected="18" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="98"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="93"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="93"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Patrick Verschueren</name_or_title>
      <organization>University Hospitals Leuven</organization>
      <phone>+32 16 34 25 41</phone>
      <email>patrick.verschueren@uzleuven.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

